Search Within

Shanu Modi

  1. "Survivorship Research"
Formats
  1. Meeting Abstract (64)
  2. Journal Article (49)
Groups
  1. Breast Medicine Service (113)
  2. Department of Medicine (113)
  3. Solid Tumor Oncology Division (113)
  4. Survivorship Research (113)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (71)
  6. Epidemiology and Biostatistics (70)

More Groups

People
  1. Clifford Hudis (79)
  2. Larry Norton (50)
  3. Sujata Patil (43)
  4. Chau Dang (41)
  5. Sarat Chandarlapaty (36)
  6. Diana Lake (33)

More People

Years
  1. 2024 (7)
  2. 2023 (4)
  3. 2022 (5)
  4. 2021 (3)
  5. 2020 (7)
  6. 2019 (9)

More Years

Publications
  1. Journal of Clinical Oncology (31)
  2. Cancer Research (23)
  3. Breast Cancer Research and Treatment (11)
  4. Clinical Breast Cancer (7)
  5. Clinical Cancer Research (7)
  6. Annals of Oncology (5)

More Publications

Publishers
  1. American Association for Cancer Research (32)
  2. American Society of Clinical Oncology (32)
  3. Springer (11)
  4. Elsevier Inc. (9)
  5. Oxford University Press (8)
  6. American Medical Association (6)

More Publishers

Results (113)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot study of dose-dense paclitaxel with trastuzumab and lapatinib for node-negative HER2-overexpressed breast cancer
    Journal Article

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S. M.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G. M.; Drullinsky, P. R.; Gajria, D.; Goldfarb, S. B.; Comen, E. A.; more...
    Clinical Breast Cancer (2016)

    Fulltext@MSK | Save
  • Development of a noninvasive assay to determine drug concentration in tumor during hsp90 inhibitor therapy
    Meeting Abstract

    Taldone, T.; Pillarsetty, N.; Dunphy, M. P. S.; Gerecitano, J. F.; Caldas-Lopes, E.; Beattie, B.; Peter, R. I.; Kang, Y. L.; Rodina, A.; Yan, P.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Dickler, M. N.; Ulaner, G.; Zamora, S. J.; Sterlin, V.; Iasonos, A.; Coughlin, C. M.; Morozov, A.; Ero, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Ulaner, G.; Zamora, S.; Sterlin, V.; Iasonos, A.; Dickler, M. N.; Moynahan, M. E.; Hudis, C. A.; Baselga, J.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • A phase I clinical trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer
    Meeting Abstract

    Jhaveri, K.; Cadoo, K.; Chandarlapaty, S.; Teplinsky, E.; Speyer, J.; D'Andrea, G.; Patil, S.; Haque, S.; Friedman, K.; Heese, S.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy
    Meeting Abstract

    Gajria, D.; Modi, S.; Saura, C.; Sakr, R.; Solano, K.; Won, H.; Pannu, H.; Patil, S.; Lake, D.; Traina, T.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save